DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Key Highlights
- ➤ReMEDy2 enrollment reaches 200 participants; interim analysis expected Q1 2027
- ➤FGR trial completes enrollment in first two cohorts, totaling 12 participants
- ➤Cash, equivalents and short-term investments fall to $34.9 million
- ➤Cash runway expected to fund operations and planned studies into Q4 2027
- ➤Nine-month net loss rises to $31.5 million from $24.0 million
Expert Statements
Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics
“During the third quarter and recent weeks, we continued to advance DM199 across each of our clinical programs, including completing enrollment in the first two cohorts of our Phase 2 early-onset fetal growth restriction study and reaching the 200-participant enrollment threshold for the planned interim analysis of ReMEDy2”
Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics
“We believe these programs address serious diseases in which impaired blood flow and vascular dysfunction play a meaningful role and where new treatment options are needed.”
Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics
“We look forward to presenting preliminary results from the first two FGR cohorts at our November 24 key opinion leader (KOL) event and to the ReMEDy2 interim analysis expected in the first quarter of 2027.”
Julie Krop, MD, Chief Medical Officer of DiaMedica Therapeutics
“Our clinical programs are providing important opportunities to evaluate the pharmacologic effects of DM199 across pregnancy-related vascular disorders and acute ischemic stroke,”
Julie Krop, MD, Chief Medical Officer of DiaMedica Therapeutics
“In preeclampsia, the Part 1a results demonstrated rapid and sustained reductions in maternal blood pressure and supported advancement into studies of early-onset disease.”
Julie Krop, MD, Chief Medical Officer of DiaMedica Therapeutics
“In FGR, enrollment of the first two dose cohorts has now been completed, and we look forward to reviewing the preliminary safety and clinical findings with leading maternal-fetal medicine experts later this month.”
Julie Krop, MD, Chief Medical Officer of DiaMedica Therapeutics
“In ReMEDy2, reaching the 200-participant threshold enables the prespecified interim analysis in AIS once the 200th participant completes their 90-day follow-up.”
DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
* Enrollment Complete in First Two Cohorts of Phase 2 Early-Onset Fetal Growth Restriction Trial; KOL Event Featuring Preliminary Results Scheduled for November 24
Get started
Create a free account to read the full story.